flowchart TD
Bemdaneprocel_for_Parkinson_s_["Bemdaneprocel for Parkinson's Disease"] -->|"references"| AADC["AADC"]
Bemdaneprocel_for_Parkinson_s_["Bemdaneprocel for Parkinson's Disease"] -->|"references"| TH["TH"]
style Bemdaneprocel_for_Parkinson_s_ fill:#4fc3f7,stroke:#333,color:#000
| Field | Value | |-------|-------| | NCT Number | [NCT06944522](https://clinicaltrials.gov/study/NCT06944522) | | Status | Recruiting | | Sponsor | BlueRock Therapeutics (Bayer) | | Phase | Phase 1/2 | | Intervention | Bemdaneprocel (BIOL) + Sham surgery |
Therapy Overview
[Bemdaneprocel](https://www.bluerocktx.com/pipeline/bemdaneprocel/) is a cell therapy product consisting of pluripotent stem cell-derived dopaminergic progenitors. These cells are designed to replace the lost dopamine-producing neurons in the substantia nigra of PD patients.
Mechanism
The therapy involves:
Cell source: Human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs) differentiated into midbrain dopaminergic neurons
Transplantation: Surgical implantation into the striatum
Integration: Cells mature into functional dopamine-producing neurons that integrate into existing neural circuits
Restoration: Restore dopamine signaling and improve motor function
Previous Development
...
Bemdaneprocel for Parkinson's Disease
Trial Overview
Mermaid diagram (expand to render)
| Field | Value | |-------|-------| | NCT Number | [NCT06944522](https://clinicaltrials.gov/study/NCT06944522) | | Status | Recruiting | | Sponsor | BlueRock Therapeutics (Bayer) | | Phase | Phase 1/2 | | Intervention | Bemdaneprocel (BIOL) + Sham surgery |
Therapy Overview
[Bemdaneprocel](https://www.bluerocktx.com/pipeline/bemdaneprocel/) is a cell therapy product consisting of pluripotent stem cell-derived dopaminergic progenitors. These cells are designed to replace the lost dopamine-producing neurons in the substantia nigra of PD patients.
Mechanism
The therapy involves:
Cell source: Human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs) differentiated into midbrain dopaminergic neurons
Transplantation: Surgical implantation into the striatum
Integration: Cells mature into functional dopamine-producing neurons that integrate into existing neural circuits
Restoration: Restore dopamine signaling and improve motor function
Previous Development
First-in-human study initiated by BlueRock Therapeutics
Acquired by Bayer in 2019 for $600M
Represents next-generation cell therapy beyond first-generation approaches like [iNSC-DAP](/clinical-trials/insk-dap-parkinson-nct05901818)
Study Design
Allocation: Randomized (active vs sham surgery control)
Blinding: Double-blind
Primary Outcome: Safety and tolerability at 12 months
Secondary Outcome: Motor function improvement (UPDRS Part III)
Significance
Bemdaneprocel represents a potentially curative approach to Parkinson's disease:
Disease-modifying: Unlike symptomatic treatments, this aims to replace lost neurons
Durable: Single treatment may provide long-lasting benefits
Precision: Cell therapy targets the specific neuronal population lost in PD
Cell Therapy for Parkinson's Disease
Evolution of Cell Replacement Therapy
Cell replacement therapy for PD has evolved through several generations[@bluerock2024][@stemcellder2024]:
First generation (1980s-1990s): Fetal ventral mesencephalon (FVM) transplantation
Limited by ethical concerns, variable outcomes, and supply constraints
Showed proof-of-concept but inconsistent results
Second generation (2000s): Embryonic stem cell-derived neurons
Improved consistency but tumor risk and ethical issues persisted
Limited by cell purity and survival rates
Third generation (2010s-present): iPSC and hESC-derived dopaminergic progenitors
Bemdaneprocel represents this generation
Defined cell product, scalable production, reduced tumor risk
Bemdaneprocel Differentiation Protocol
The differentiation process from pluripotent stem cells to midbrain dopamine (mDA) neurons involves[@kikuchi2023]:
Stem cell maintenance: Human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs)
Patterning: Exposure to morphogens (SHH, FGF8) to specify midbrain identity
Floor plate induction: Generation of floor plate intermediate progenitors
Dopaminergic differentiation: Maturation into tyrosine hydroxylase (TH)-positive neurons
Purification: Isolation of high-purity Otx2+/Lmx1a+ mDA progenitors
Formulation: Cell product ready for transplantation
Clinical Considerations
Patient Selection
Optimal candidates for cell therapy include:
Patients with confirmed idiopathic Parkinson's disease
Disease duration 5-15 years
Good response to dopaminergic medications
No significant cognitive impairment
No psychiatric comorbidities
Surgical Considerations
Stereotactic transplantation into striatum
Bilateral implantation typically performed
Immunosuppression may be required post-transplantation
[A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease - NCT06944522](https://clinicaltrials.gov/study/NCT06944522)